Sugi Predict

Sugi Predict / Compounds / SCHEMBL3279568

SCHEMBL3279568

SCHEMBL3279568

Cc1cn([C@H]2CC(OC(=O)c3ccccc3)[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ RNASE1 P07998 1/20 1.00
▸ TK1 P04183 4/20 0.56
▸ TK2 O00142 3/20 0.56
▸ POLB P06746 1/20 0.55
▸ ALB P02768 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ PMP22 Q01453 1/20 0.54
▸ TSHR P16473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22992433 1.00 RNASE1 (1.00) RNASE1TK1TK2POLBALB
SCHEMBL2056750 1.00 RNASE1 (1.00) RNASE1TK1TK2POLBALB
SCHEMBL7875887 1.00 RNASE1 (1.00) RNASE1TK1TK2POLBALB
SCHEMBL7875892 1.00 RNASE1 (1.00) RNASE1TK1TK2POLBALB
Barbituric Acid SCHEMBL9710100 0.93 RNASE1 (0.86) RNASE1TK1TK2POLB
SCHEMBL9326675 0.90 RNASE1 (0.82) RNASE1TK1TK2
SCHEMBL13273339 0.90 RNASE1 (0.82) RNASE1TK1TK2
SCHEMBL21886791 0.90 RNASE1 (0.82) RNASE1TK1TK2
SCHEMBL22992340 0.90 RNASE1 (0.82) RNASE1TK1TK2
SCHEMBL30976654 0.90 RNASE1 (0.82) RNASE1TK1TK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087634-A1 Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides BERRY & ASSOCIATES, INC. (US) 2010-04-08 — — US disclosed
EP-1831238-A2 FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES Berry & Associates , Inc. (US) 2007-09-12 — — EP disclosed
US-20060178507-A1 Fluorous oligonucleotide reagents and affinity purification of oligonucleotides BERRY & ASSOCIATES, INC. 2006-08-10 — — US disclosed
WO-2006081035-A2 FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES BERRY & ASSOCIATES, INC. (US) 2006-08-03 — — WO disclosed
US-5965721-A WITH IMPROVED NUCLEASE RESISTANCE AND IMPROVED CELLULAR UPTAKE; FOR ANTISENSE AGENTS AND REGULATION OF RNA EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1999-10-12 — — US disclosed
US-5610289-A Backbone modified oligonucleotide analogues ISIS PHARMACEUTICALS, INC. (US) 1997-03-11 — — US disclosed
US-5548076-A CONDENSING A BLOCKED NUCLEOSIDE BOUND TO A CARRIER GENENTECH, INC. (US) 1996-08-20 — — US disclosed
US-5519126-A COMBATTING DISEASES BY BIOCHEMICL INTERVENTION AT THE RNA AND DNA LEVEL UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1996-05-21 — — US disclosed
US-5495009-A TREATING WITH BROMINE IN PRESENCE OF 2,6-DIETHYLPYRIDINE AND MOLECULAR SIEVES FOLLOWED BY TREATMENT WITH TETRABUTYLAMMONIUM FLUORIDE IN TETRAHYDROFURAN GILEAD SCIENCES, INC. (US) 1996-02-27 — — US disclosed
EP-0586570-A4 BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES ISIS PHARMACEUTICALS INC (US) 1996-01-24 — — EP disclosed
US-5166330-A Phosphonation, amination and reaction with nucleosides HOECHST AKTIENGESELLSCHAFT (DE) 1992-11-24 — — US disclosed
WO-1992019637-A1 OLIGONUCLEOTIDE ANALOGS CONTAINING THIOFORMACETAL LINKAGES GILEAD SCIENCES, INC. (US) 1992-11-12 — — WO disclosed
EP-0406309-A4 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES — 1992-08-19 — — EP disclosed
EP-0406309-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1991-01-09 — — EP disclosed
US-4959463-A Intermediates GENENTECH, INC. (US) 1990-09-25 — — US disclosed
WO-1989009221-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1989-10-05 — — WO disclosed
US-4835263-A Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1989-05-30 — — US disclosed
EP-0117777-B1 COMPOUNDS CONTAINING AN OLIGONUCLEOTIDE BONDED TO AN INTERCALLATING AGENT, A PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1987-12-23 — — EP disclosed
EP-0219342-A2 Method and reagents for in vitro oligonucleotide synthesis GENENTECH, INC. (US) 1987-04-22 — — EP disclosed
EP-0117777-A1 Compounds containing an oligonucleotide bonded to an intercallating agent, a process for their preparation and their application Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1984-09-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178507-A1 Fluorous oligonucleotide reagents and affinity purification of oligonucleotides DCLRE1B, POLM, FBL RNASE1 171/4885TK1 23/4885TK2 460/4885
US-20100087634-A1 Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides DCLRE1B, POLM, FBL RNASE1 171/4885TK1 23/4885TK2 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.